Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

April CHMP Meeting: Disappointment In Advance For AB Science, Gilead Hopeful On Biktarvy

Apr 25 2018

• By Maureen Kenny

3d different tablets and pills on a white background with question marks — Which new drugs will the EMA recommend for approval this week? • Source: Shutterstock

Related Content

EU CAR-T Race Tightens After Yescarta Reverts To Standard Review

Apr 23 2018

EU Indication Extensions On Cards For Taltz, Truvada and Yervoy

Dec 19 2017

‘Outstanding Issues’ Near For Products Approaching EU Review End – Including Neulasta Biosimilar

Dec 15 2017

Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations

Oct 15 2017

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Mar 23 2018

Gilead's Biktarvy Approval Heightens HIV Competition With ViiV

Feb 07 2018

Related Companies

Gilead Sciences, Inc.

Talphera, Inc.

Portola Pharmaceuticals, Inc.

Radius Health, Inc.

Eurocept Pharmaceuticals

Takeda Pharmaceutical Co. Ltd.

Sarepta Therapeutics, Inc.

Ionis Pharmaceuticals, Inc.

Kite Pharma, Inc.

Novartis AG

Eli Lilly and Company

Roche Holding AG

Additional Topics

Europe Drug Review Approvals Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window